Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer

In recent research, treatment with osimertinib plus a platinum–pemetrexed chemotherapy combination resulted in statistically significant and clinically meaningful improvement in overall survival in patients with newly diagnosed EGFR-mutated advanced non-small cell lung cancer (NSCLC) compared to osimertinib alone.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup